Drug-coated balloon in combination with bare metal stent strategy for de novo coronary artery disease: A PRISMA-compliant meta-analysis of randomized clinical trials.

However, DCB + BMS had nonsignificantly lower LLL than BMS alone (in-segment LLL: MD, −0.14; 95% CI, −0.33–0.04; P = 0.24), and was more advantageous in reducing MACE incidence, with borderline significance (MACEs: RR, 0.67; 95% CI, 0.45–0.99; P = 0.05).

also in 6,432 other papers

The subgroup analysis showed that the DCB + BMS strategy was advantageous over the BMS treatment in reducing MACEs incidence, with borderline significant (RR, 0.67; 95% CI, 0.45–0.99; P = 0.05; Fig. 2 B). 3.3.

also in 10,359 other papers